Related Company: More Than 3,100 People Volunteer For Vaccine Study Vermont Business Magazine The University of Vermont Medical Center and the Vaccine Testing Center at the University of Vermont's Larner College of Medicine have successfully reached and surpassed the targeted number of enrollees for an ongoing Phase 3 clinical trial of the AstraZeneca COVID-19 vaccine. The goal of 250 enrolled and dosed volunteers was met in just four weeks – with more than 3,100 people registering to take part. The local vaccine trial was able to enroll nearly 65 percent of volunteers who are over the age of 65 – a critically important demographic for testing efficacy and safety and a unique, local contribution to the nation-wide study. Additionally, more than 12 percent of participants identify as black, indigenous or persons of color.